These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29925070)

  • 1. Osmoregulation in Polycystic Kidney Disease: Relationship with Cystogenesis and Hypertension.
    Underwood CF; Phillips JK; Hildreth CM
    Ann Nutr Metab; 2018; 72 Suppl 2():33-38. PubMed ID: 29925070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.
    Ho TA; Godefroid N; Gruzon D; Haymann JP; Maréchal C; Wang X; Serra A; Pirson Y; Devuyst O
    Kidney Int; 2012 Nov; 82(10):1121-9. PubMed ID: 22718190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased water intake decreases progression of polycystic kidney disease in the PCK rat.
    Nagao S; Nishii K; Katsuyama M; Kurahashi H; Marunouchi T; Takahashi H; Wallace DP
    J Am Soc Nephrol; 2006 Aug; 17(8):2220-7. PubMed ID: 16807403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hydration in rats and mice with polycystic kidney disease.
    Hopp K; Wang X; Ye H; Irazabal MV; Harris PC; Torres VE
    Am J Physiol Renal Physiol; 2015 Feb; 308(3):F261-6. PubMed ID: 25503729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The medicinal use of water in renal disease.
    Wang CJ; Grantham JJ; Wetmore JB
    Kidney Int; 2013 Jul; 84(1):45-53. PubMed ID: 23423255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin: physiology, assessment and osmosensation.
    Bankir L; Bichet DG; Morgenthaler NG
    J Intern Med; 2017 Oct; 282(4):284-297. PubMed ID: 28649750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic Kidney Disease and the Vasopressin Pathway.
    van Gastel MDA; Torres VE
    Ann Nutr Metab; 2017; 70 Suppl 1():43-50. PubMed ID: 28614813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydration and Chronic Kidney Disease Progression: A Critical Review of the Evidence.
    Clark WF; Sontrop JM; Huang SH; Moist L; Bouby N; Bankir L
    Am J Nephrol; 2016; 43(4):281-92. PubMed ID: 27161565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic kidney disease and the flyer.
    Rayman RB
    Aviat Space Environ Med; 1985 Nov; 56(11):1105-6. PubMed ID: 4074266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease.
    Tao S; Kakade VR; Woodgett JR; Pandey P; Suderman ED; Rajagopal M; Rao R
    Kidney Int; 2015 Jun; 87(6):1164-75. PubMed ID: 25629553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
    Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
    Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of anemia and its relationship with renal function, blood pressure, and erythropoietin in rats with chronic kidney disease.
    Phillips JK; Boyd R; Krockenberger MB; Burgio G
    Vet Clin Pathol; 2015 Sep; 44(3):342-54. PubMed ID: 26292198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in understanding the pathogenesis of polycystic kidney disease: therapeutic implications.
    Cowley BD
    Drugs; 2004; 64(12):1285-94. PubMed ID: 15200344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects.
    Bankir L
    Cardiovasc Res; 2001 Aug; 51(3):372-90. PubMed ID: 11476728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.
    Aihara M; Fujiki H; Mizuguchi H; Hattori K; Ohmoto K; Ishikawa M; Nagano K; Yamamura Y
    J Pharmacol Exp Ther; 2014 May; 349(2):258-67. PubMed ID: 24570071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
    Gattone VH; Wang X; Harris PC; Torres VE
    Nat Med; 2003 Oct; 9(10):1323-6. PubMed ID: 14502283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.
    Chapman AB; Johnson A; Gabow PA; Schrier RW
    N Engl J Med; 1990 Oct; 323(16):1091-6. PubMed ID: 2215576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension?
    Bankir L; Bichet DG; Bouby N
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F917-28. PubMed ID: 20826569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.
    Gattone VH; Maser RL; Tian C; Rosenberg JM; Branden MG
    Dev Genet; 1999; 24(3-4):309-18. PubMed ID: 10322639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.